Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data

Core Insights - Gossamer Bio, Inc. (NASDAQ:GOSS) is recognized as one of the 12 best multibagger stocks to consider for investment heading into 2026 due to strong one-year returns and upside potential [1] Company Developments - Gossamer Bio is advancing seralutinib in two late-stage pulmonary hypertension programs, maintaining high analyst confidence [2] - By the end of Q3 2025, Gossamer Bio confirmed the completion of enrollment in its global Phase 3 PROSERA study for pulmonary arterial hypertension, with 390 patients enrolled [3] - The PROSERA study is a double-blind, placebo-controlled trial evaluating seralutinib on top of background therapy, focusing on the six-minute walk distance at 24 weeks as the primary endpoint [3] - Topline data from the PROSERA study is expected to be released in February 2026 [4] - Gossamer Bio has activated the first clinical site for its registrational Phase 3 SERANATA study, which targets pulmonary hypertension associated with interstitial lung disease, broadening the clinical scope of seralutinib [4] Analyst Sentiment - Positive analyst sentiment surrounds Gossamer Bio, with Piper Sandler analyst Yasmeen Rahimi reiterating a "Buy" rating and setting a price target of $15.00 on December 9, 2025 [5] - H.C. Wainwright analyst Patrick Trucchio also issued a "Buy" rating with a $10.00 price target on November 19, 2025, citing the steady advancement of both PROSERA and SERANATA as key milestones [5] Company Profile - Gossamer Bio, Inc. is a late-stage biopharmaceutical company focused on developing seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease [6]